Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 20.07.2026 8 Aliment Pharmacol Ther 1 Am J Gastroenterol 5 BMC Gastroenterol 2 Clin Gastroenterol Hepatol 1 Clin Res Hepatol Gastroenterol 2 Dig Dis Sci 2 Eur J Gastroenterol Hepatol 2 Gastroenterology 4 Inflamm Bowel Dis 6 J Crohns Colitis 1 J Gastroenterol 2 Lancet Gastroenterol Hepatol 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. VISSER EH, Voshaar MAO, van Linschoten RCA, Bodelier AGL, et al
   A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost-Effective: Results of the Multicentre IBD Value Study.
   Aliment Pharmacol Ther. 2026;64:313-325.
   PubMed         Abstract available
   
   
2. BATRA G, Shukla A, Chatterjee A, Chandnani S, et al
   Meta-Analysis: Crohn's Disease Exclusion Diet for Induction and Maintenance in Crohn's Disease.
   Aliment Pharmacol Ther. 2026 Jul 12. doi: 10.1111/apt.70857.
   PubMed         Abstract available
   
   
3. ERNEST-SUAREZ K, Hoentjen F
   Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring.
   Aliment Pharmacol Ther. 2026 Jul 13. doi: 10.1111/apt.70858.
   PubMed        
   
   
4. 
   Correction to 'Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial'.
   Aliment Pharmacol Ther. 2026 Jul 14. doi: 10.1111/apt.70861.
   PubMed        
   
   
5. ETCHEGARAY A, Goetz N, Hanigan K, Phillips J, et al
   Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis.
   Aliment Pharmacol Ther. 2026 Jul 18. doi: 10.1111/apt.70825.
   PubMed         Abstract available
   
   
6. RICHARD N, Fumery M
   Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? Authors' Reply.
   Aliment Pharmacol Ther. 2026 Jul 15. doi: 10.1111/apt.70847.
   PubMed        
   
   
7. MARTINEZ AS, Mercader PM, Cuquerella JT, Watts MMB, et al
   Impact of Inflammatory Activity on Anorectal Function in Patients With Ulcerative Colitis: A Prospective Study.
   Aliment Pharmacol Ther. 2026 Jul 15. doi: 10.1111/apt.70855.
   PubMed         Abstract available
   
   
8. SATTAYALERTYANYONG O, Nugent Z, Barr B, Bernstein KN, et al
   Inflammatory Bowel Disease Is Associated With an Increased Risk of End-Stage Renal Disease: A Population-Based Cohort Study.
   Aliment Pharmacol Ther. 2026 Jul 14. doi: 10.1111/apt.70845.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

9. EVERHOV AH, Eriksson J, Soderling J, Askling J, et al
   Absolute risk of malignancy by treatment in patients with Crohn's disease compared to the general population: a nationwide population-based cohort study.
   Am J Gastroenterol. 2026 Jul 16. doi: 10.14309/ajg.0000000000004119.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

10. ZHU C, Wang M, Meng L, Zhao Z, et al
    Gut microbiota dysbiosis in the pathogenesis of ulcerative colitis and the therapeutic efficacy of fecal microbiota transplantation: a meta-analysis.
    BMC Gastroenterol. 2026 Jul 15. doi: 10.1186/s12876-026-05091.
    PubMed         Abstract available
    
    
11. CHEN S, Shi Y, Pang Y, Wang X, et al
    Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review.
    BMC Gastroenterol. 2026 Jul 16. doi: 10.1186/s12876-026-05116.
    PubMed         Abstract available
    
    
12. EID RA, Fakhry NA, Ahmed DM, Hodeib M, et al
    Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease.
    BMC Gastroenterol. 2026;26:455.
    PubMed         Abstract available
    
    
13. TONKAZ G, Can HH, Cinar E, Onal O, et al
    Relationship between sacroiliac joint involvement and intestinal disease activity in newly diagnosed Crohn's disease.
    BMC Gastroenterol. 2026 Jul 16. doi: 10.1186/s12876-026-05122.
    PubMed         Abstract available
    
    
14. LAFORCE-VAN LIEROP LMA, Dang R, Narula N, Ingram RJM, et al
    The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease.
    BMC Gastroenterol. 2026 Jul 17. doi: 10.1186/s12876-026-05046.
    PubMed         Abstract available
    
    

    
    Clin Gastroenterol Hepatol

15. HEGDE Y, Battula S, Ohiri C, Piasecki TM, et al
    Low Sensitivity of Commercial Assays for Measles Seroprotection in Adult Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2026 Jul 14:S1542-3565(26)00489.
    PubMed        
    
    
16. PINERO G, Manosa M, Bastida G, Ricart E, et al
    Time trends in strategies for postoperative Crohn's disease management and long-term surgical recurrence: ENEIDA registry data.
    Clin Gastroenterol Hepatol. 2026 Jul 15:S1542-3565(26)00519.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

17. CHEN Z, Zhu W, Liu G, Yu B, et al
    Integrative Analysis of Genetic and Cellular Interactions Connecting Inflammatory Bowel Disease and Primary Biliary Cholangitis.
    Clin Res Hepatol Gastroenterol. 2026 Jul 14:102885.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

18. FU X, Wang D
    Patient-Derived Claims Data on 5-ASA Utilization in Ulcerative Colitis: Strengths, Limitations, and Future Directions.
    Dig Dis Sci. 2026 Jul 11. doi: 10.1007/s10620-026-10117.
    PubMed        
    
    
19. OLSON CG, Francis FF, Yan IK, Nakhleh R, et al
    Abnormal MUC1 Expression as a Biomarker for Pouchitis.
    Dig Dis Sci. 2026;71:2211-2217.
    PubMed         Abstract available
    
    

    
    Eur J Gastroenterol Hepatol

20. BODGER K, Taylor F, Rai P, Dobson L, et al
    Factors associated with preference for in-person versus remote consultations in inflammatory bowel disease in the United Kingdom: secondary analysis of an online survey.
    Eur J Gastroenterol Hepatol. 2026 Jun 4. doi: 10.1097/MEG.0000000000003220.
    PubMed         Abstract available
    
    
21. MALKOPOULOS A, Subhaharan D, James R, Jones M, et al
    Management of endoscopic rectal activity in ulcerative colitis: real-world adherence to guidelines and clinical outcomes.
    Eur J Gastroenterol Hepatol. 2026 Jun 2. doi: 10.1097/MEG.0000000000003228.
    PubMed         Abstract available
    
    

    
    Gastroenterology

22. THOMPSON KN, Ma S, Bhosle A, Nickols WA, et al
    Harmonized metagenomic signatures of the gut microbiome reveal robust species, functions, and strain links to inflammatory bowel disease.
    Gastroenterology. 2026 Jul 14:S0016-5085(26)07044.
    PubMed         Abstract available
    
    
23. ST-PIERRE J, Gold SL, Haskey N, Damas OM, et al
    Nutrition and Body Composition: Missing Outcomes in Appetite- and Weight-Modifying Therapies for Individuals with Inflammatory Bowel Disease.
    Gastroenterology. 2026 Jul 13:S0016-5085(26)07041.
    PubMed        
    
    

    
    Inflamm Bowel Dis

24. GEORGE AT, Gottlieb K, Colucci DR, Eastman WJ, et al
    Artificial intelligence assessment of endoscopic severity and extent: A machine learning approach to continuous evaluation of endoscopic inflammation in ulcerative colitis.
    Inflamm Bowel Dis. 2026 Jul 17:izag135. doi: 10.1093.
    PubMed         Abstract available
    
    
25. KUENZIG ME, Bernstein CN, Coward S, Dummer TJB, et al
    The association between artificial light at night and inflammatory bowel disease incidence, surgery, and health services utilization: population-based observational studies.
    Inflamm Bowel Dis. 2026 Jul 17:izag141. doi: 10.1093.
    PubMed         Abstract available
    
    
26. KURIAKOSE KUZHIYANJAL AJ, Rhodes S, Sethi-Arora K, Hancock L, et al
    Healthcare professionals' knowledge, attitudes, and practice with addressing sexual health among people living with inflammatory bowel disease: A UK cross-sectional survey.
    Inflamm Bowel Dis. 2026 Jul 10:izag121. doi: 10.1093.
    PubMed         Abstract available
    
    
27. GILL PK, Finch H, Stein L, Kaplan GG, et al
    Underevaluation of bowel urgency in clinical care: patient experiences and outcomes in ulcerative colitis: a retrospective cohort study.
    Inflamm Bowel Dis. 2026 Jul 17:izag102. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

28. 
    Correction to: P0562 Comparative Efficacy and Safety of Upadacitinib Versus Oral Prednisolone for the Induction of Remission in Ulcerative Colitis: A Prospective, Multicenter, Open-label, Randomized Controlled Trial (PREDUPA Trial) Protocol and P0563
    J Crohns Colitis. 2026;20:jjag010.
    PubMed        
    
    
29. GIUSTO EA, Pinton P, Giorgi C, Serino G, et al
    Intestinal cancer risk in Crohn's disease: authors' reply on methods, data integrity, and clinical implications.
    J Crohns Colitis. 2026;20:jjag097.
    PubMed        
    
    
30. BARA R, Barruscotti A, Gianferrari M, Allocca M, et al
    Henoch-Schonlein purpura following adalimumab treatment optimization for Crohn's disease: a letter to the editor.
    J Crohns Colitis. 2026;20:jjag098.
    PubMed        
    
    
31. SATTAYALERTYANYONG O, Nugent Z, Bernstein CN
    All-cause and cause-specific mortality in inflammatory bowel disease across the biologic era: a population-based matched cohort study.
    J Crohns Colitis. 2026;20:jjag105.
    PubMed         Abstract available
    
    
32. 
    Correction to: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
    J Crohns Colitis. 2026;20:jjag090.
    PubMed        
    
    
33. MASSIRONI S, Mulinacci G, Zuin G, Civitelli F, et al
    Comparative performance of intestinal ultrasound activity indices in pediatric ulcerative colitis: a prospective study.
    J Crohns Colitis. 2026;20:jjag106.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

34. XU W, Wang W, Song L
    Letter to the Editor to "Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease".
    J Gastroenterol. 2026 Jul 16. doi: 10.1007/s00535-026-02483.
    PubMed        
    
    

    
    Lancet Gastroenterol Hepatol

35. REINISCH W, Stepek D, Kempinski R, Danese S, et al
    Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2026 Jul 16:S2468-1253(26)00120.
    PubMed         Abstract available
    
    
36. JAIRATH V, Kierkus J, Duvall GA, Danese S, et al
    Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2026 Jul 16:S2468-1253(26)00119.
    PubMed         Abstract available
    
    

    
    PLoS One

37. KHAN N, Nasir MM, Aziz U, Manzoor H, et al
    Integrative metagenomics and structural bioinformatics identify explainable gut microbial variants associated with Crohn's disease.
    PLoS One. 2026;21:e0340748.
    PubMed         Abstract available
    
    
38. DA SILVA MQ, Souza Menezes JD, Esteves Francisco JL, Michele da Silva F, et al
    A scoping review on emerging biomarkers in inflammatory bowel disease: Towards precision medicine in diagnosis and therapeutic management.
    PLoS One. 2026;21:e0353295.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum